NUVB Nuvation Bio Inc. Insider Trading

Director Robert Mashal buys 25,000 shares of NUVB at $4.73; all 4 prior same-ticker purchases show 90d gains, currently -51.2% from 52-week high

Director Robert Mashal purchased 25,000 shares at $4.73, increasing his holdings to 225,000 shares (+12.5% increase). His track record at NUVB is notable: all 4 prior open-market purchases at this ticker showed positive 90-day returns (ranging from +16.8% to +29.4%), indicating consistent timing on the buy side. The current price of $4.76 sits -51.2% from the 52-week high of $9.75, meaning the stock has declined substantially from recent peaks. Fundamentally, the company posted $83.2M in revenue and $5.4M net income in its latest quarter, alongside +699.0% annual revenue growth, though it remains unprofitable on a full-year basis, creating a contrast between strong top-line momentum and unresolved profitability concerns.

Director BLICKENSTAFF KIM D initiates new NUVB position — buys 172,189 shares at $2.90, total $500,088.51

Director BLICKENSTAFF KIM D established a brand-new position in Nuvation Bio Inc. (NUVB), purchasing 172,189 shares at $2.90 per share for a total of $500,088.51, moving from 0 shares to 172,189 shares post-transaction. The purchase was made at $2.90, while the current price stands at $2.99, and the stock sits -24.7% from its 52-week high of $3.97, though it has gained +31.1% over the prior 90 days. The initiation of a $500,088.51 position by a Director at a company with a market cap of $739.0M and a net income of $-14,792,000.00 is notable given the unprofitable fiscal year backdrop. The scale of the purchase — representing a full new position rather than an addition — is the primary signal investors may want to monitor alongside the company's path toward profitability.